Given that ferroptosis can enhance tumor antigenicity and immune cell recruitment, therapeutic combinations involving ferroptosis inducers and immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies) may represent a rational next step for clinical development. Here, CD274 is linked to neoplasm.